Molecular Design of Peptide-Fc Fusion Drugs
-
Published:2019-05-22
Issue:3
Volume:20
Page:203-208
-
ISSN:1389-2002
-
Container-title:Current Drug Metabolism
-
language:en
-
Short-container-title:CDM
Author:
Ning Lin1, He Bifang1, Zhou Peng1, Derda Ratmir2, Huang Jian1
Affiliation:
1. Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu, China 2. Department of Chemistry, University of Alberta, Alberta, Canada
Abstract
Background:Peptide-Fc fusion drugs, also known as peptibodies, are a category of biological therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest. However, to develop such kind of drugs is laborious and expensive. Rational design is urgently needed.Methods:We summarized the key steps in peptide-Fc fusion technology and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs. We also raised open questions about the computer-aided molecular design of peptide-Fc.Results:The design of peptibody consists of four steps. First, identify peptide leads from native ligands, biopanning, and computational design or prediction. Second, select the proper Fc region from different classes or subclasses of immunoglobulin. Third, fuse the peptide leads and Fc together properly. At last, evaluate the immunogenicity of the constructs. At each step, there are quite a few useful resources and computational tools.Conclusion:Reviewing the molecular design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.
Funder
Sichuan Province Science and Technology Support Program Fundamental Research Funds for the Central Universities of China National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference89 articles.
1. Lau JL, Dunn MK. Bioorg Med Chem, Therapeutic peptides: Historical perspec- tives, current development trends, and future directions.,, 2017, 26,, 2700-2707, 2. Otvos L, Vetter SW, Koladia M, Knappe D, Schmidt R, Ostorhazi E, Kovalszky I, Bionda N, Cudic P, Surmacz E, Wade JD, Hoffmann R. Amino Acids, The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight bind- ing to the receptor.,, 2014, 46,, 873-882, 3. Werle M, Bernkop-Schnurch A. Amino Acids, Strategies to improve plasma half life time of peptide and protein drugs.,, 2006, 30,, 351-367, 4. Cavaco M, Castanho M, Neves V. Biopolymers, Peptibodies: An elegant solution for a long-standing problem.,, 2017, 30,, e23095-, 5. Shimamoto G, Gegg C, Boone T, Queva C. MAbs, Peptibodies: A flexible alternative format to antibodies.,, 2012, 4,, 586-59,
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|